[{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"YolTech Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"YOLT-101","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.14999999999999999,"dosageForm":"Infusion","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ SHENZHEN SALUBRIS PHARMACEUTICALS","highestDevelopmentStatusID":"6","companyTruncated":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ SHENZHEN SALUBRIS PHARMACEUTICALS"},{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"Salubris Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Financing","leadProduct":"JK07","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ SHENZHEN SALUBRIS PHARMACEUTICALS","highestDevelopmentStatusID":"8","companyTruncated":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ SHENZHEN SALUBRIS PHARMACEUTICALS"},{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Enarodustat","moa":"Egl nine homolog 1","graph1":"Hematology","graph2":"Approved FDF","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Inapplicable"},{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Allisartan Isoproxil","moa":"Angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Inapplicable"},{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Allisartan Isoproxil","moa":"Angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Inapplicable"},{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SAL067","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase III","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Inapplicable"},{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SAL067","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase III","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Inapplicable"},{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SAL-0951","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Inapplicable"},{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SAL-0951","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Inapplicable"},{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SAL-0951","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Inapplicable"},{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SAL067","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase III","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Inapplicable"},{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Inapplicable"},{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SAL001","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Inapplicable"},{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"SHENZHEN SALUBRIS PHARMACEUTICALS","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Enadustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Phase IV","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ SHENZHEN SALUBRIS PHARMACEUTICALS","highestDevelopmentStatusID":"11","companyTruncated":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ SHENZHEN SALUBRIS PHARMACEUTICALS"},{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SAL-0951","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase III","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Inapplicable"},{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"Carlyle","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"JK07","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0.26000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.26000000000000001,"dosageForm":"Undisclosed","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Carlyle","highestDevelopmentStatusID":"6","companyTruncated":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Carlyle"},{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH1R","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Undisclosed"},{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"SAL0140","moa":"Aldosterone","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Undisclosed"},{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Enarodustat","moa":"Egl nine homolog 1","graph1":"Nephrology","graph2":"Phase IV","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Undisclosed"},{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"SAL0133","moa":"SARS-CoV-2 3CLpro","graph1":"Undisclosed","graph2":"Phase I","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by SHENZHEN SALUBRIS PHARMACEUTICALS CO.LTD
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target